Associated Papers
Precision medicine advances in pancreatic cancer driven by genomic and molecular alterations.
Li X et al.
World Journal of Gastrointestinal Oncology, 2025
Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations.
Leini R et al.
Scientific Reports, 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
Riedl JM et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.
Chen Y et al.
Molecular Cancer Therapeutics, 2025
Comprehensive analysis of KRAS aberrations in pan-cancer, with a focus on prognostic and therapeutic implications.
Jung J et al.
Therapeutic Advances in Medical Oncology, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.
Ros J et al.
International Journal of Molecular Sciences, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A et al.
Biomarker Research, 2024
Unveiling the role of KRAS in tumor immune microenvironment.
Xu M et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.
Rekowska AK et al.
Biomedicines, 2024
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.
Nussinov R et al.
Annual Review of Pharmacology and Toxicology, 2024
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J et al.
Nature Medicine, 2024
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA et al.
Cancer Research, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A et al.
The New England Journal of Medicine, 2023
KRAS inhibition in metastatic colorectal cancer: An update.
Nusrat M et al.
Current Opinion in Pharmacology, 2023
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H et al.
Cancer Communications (london, England), 2023
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M et al.
Current Treatment Options in Oncology, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A et al.
Cancer Discovery, 2022
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Hofmann MH et al.
Cancer Discovery, 2022
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Reita D et al.
Cancers, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Targeting KRAS G12C mutation in lung adenocarcinoma.
Rohatgi A et al.
Lung Cancer (amsterdam, Netherlands), 2022
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
Tsai YS et al.
The Journal of Clinical Investigation, 2022
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.
Zhuang H et al.
Frontiers in Oncology, 2022
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.
Brazel D et al.
Lung Cancer (auckland, N.z.), 2022
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.
Ho CSL et al.
European Journal of Cancer (oxford, England : 1990), 2021
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D et al.
Molecular Cancer, 2021
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Tanaka N et al.
Cancer Discovery, 2021
Emerging strategies to target RAS signaling in human cancer therapy.
Chen K et al.
Journal of Hematology & Oncology, 2021
Acquired Resistance to KRASG12C Inhibition in Cancer.
Awad MM et al.
The New England Journal of Medicine, 2021
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.
Garcia-Robledo JE et al.
Therapeutic Advances in Respiratory Disease, 0